RESUMO
BACKGROUND: Toothbrushes may get contaminated by the oral cavity, environment, hands, storage containers, or aerosol contamination. The present study was conducted to assess the microbial contamination of toothbrushes and methods of their decontamination. MATERIALS AND METHODS: The current study included 160 subjects of both genders. All the subjects were provided with a toothbrush and paste with complete hygiene instructions for the oral cavity. After one month, all the brushes were collected. The samples were categorized into four groups of 40 each. Group I was treated with 0.2% chlorhexidine gluconate, group II with Listerine, group III with Dettol, and group IV with tap water. Finally, these toothbrushes were placed in 5 mL of neutralizer broth and then evaluated to study the efficacy of four disinfectants. All the data were analyzed using the statistical package for social science (SPSS) version 23 software (IBM, Armonk, NY, USA). For all analyses, p < 0.05 was considered to be statistically significant Results: Aerobic bacterial growth before disinfection in Groups I, II, III, and IV was 91.6%, 75.84%, 75%, 81.67%, respectively (p = 0.01). After disinfecting the brushes aerobic bacterial growth was reduced to 34.17%, 30.84%, 24.17% & 74.17% in Groups I, II, III, and IV, respectively (p = 0.002). Klebsiella, Micrococci and Escherichia coli survived the most even after disinfection was done. CONCLUSION: Most effective agent for the disinfection of toothbrushes was Dettol followed by Listerine and 0.2% chlorhexidine gluconate. Tap water was found to be ineffective in the decontamination of toothbrushes.
RESUMO
The global pandemic of coronavirus disease-2019 (COVID-19) has led to significant disruptions in healthcare delivery. Patients with chronic liver diseases require a high level of care and are therefore particularly vulnerable to disruptions in medical services during COVID-19. Recent data have also identified chronic liver disease as an independent risk factor for COVID-19 related hospital mortality. In response to the pandemic, national and international societies have recommended interim changes to the management of patients with liver diseases. These modifications included the implementation of telehealth, postponement or cancelation of elective procedures, and other non-urgent patient care-related activities. There is concern that reduced access to diagnosis and treatment can also lead to increased morbidity in patients with liver diseases and we may witness a delayed surge of hospitalizations related to decompensated liver disease after the COVID-19 pandemic has receded. Therefore, it is paramount that liver practices craft a comprehensive plan for safe resumption of clinical operations while minimizing the risk of exposure to patients and health-care professionals. Here, we provide a broad roadmap for how to safely resume care for patients with chronic liver disease according to various phases of the pandemic with particular emphasis on outpatient care, liver transplantation, liver cancer care, and endoscopy.